TL-895 and KRT-232 Study in Acute Myeloid Leukemia

This study evaluates TL-895, a potent, orally available and highly selective irreversible tyrosine kinase inhibitor combined with navtemadlin (KRT-232), a novel oral small molecule inhibitor of MDM2 for the treatment of adults with FLT3 mutated Acute Myeloid Leukemia. Participants must be relapsed/refractory (e.g., having failed prior therapy) to be eligible for this study.

Additional locations may be listed on ClinicalTrials.gov for NCT04669067.

See trial information on ClinicalTrials.gov for a list of participating sites.

Trial PhasePhase I/II

Trial Typetreatment

Lead OrganizationTelios Pharma, Inc.

• Primary IDTL-895-203
• Secondary IDsNCI-2021-00124
• ClinicalTrials.gov IDNCT04669067